Omni Bio Announces First Results for Its Lead Recombinant Molecule

Omni Bio Announces First Results for Its Lead Recombinant Molecule 
Fc-AAT Shown to Be Effective in Mouse Models of Gouty Arthritis 
DENVER, CO -- (Marketwire) -- 03/15/13 --  Omni Bio Pharmaceutical,
Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused
on the commercialization of new uses of alpha-1 antitrypsin (AAT) for
the treatment of a variety of medical indications and the development
of recombinant forms of AAT, today announced the first disclosure of
important results for its recombinant molecule, Fc-AAT. 
Leo A. B. Joosten, PhD, of the Radboud University Medical Center,
Nijmegen, The Netherlands, presented data on therapeutic applications
of Fc-AAT in gout at the 4th European Workshop on Crystals in Human
Diseases in Paris, France. Dr. Joosten reported on several studies
that he and colleagues performed in mouse models of gouty athritis
showing that Fc-AAT:  


 
--  Effectively suppressed pro-inflammmatory responses as measured by cell
    influx, joint swelling, IL-1β and IL-6 levels in a dose-dependent
    manner
--  Exhibited a significant reduction (85%) in these parameters at a
    relatively low dose of 50 ug (2 mg/kg per mouse) that was at
    least as effective as a high dose (10mg/mouse) of the IL1 receptor
    antagonist anakinra
--  Was at least 40 times more potent than a clinical grade of
    plasma-derived AAT
--  Exhibited a prolonged duration of action relative to plasma-derived
    AAT

  
The study also concluded that Fc-AAT has a unique mechanism of
anti-inflammatory action that occurs through modulation of TLR2 and
TLR4 expression, suppression of a variety of pro-inflammatory
cytokine mediators, inhibition of capsase-1 activation and induction
of IL1 receptor antagonism. 
Dr. Joosten commented, "These results are very exciting and suggest
that Fc-AAT has high potential for use in the treatment of refractory
gout and other inflammatory conditions. We are now considering how
best to pursue early clinical trials in patients suffering from this
condition." Omni Bio's Chief Scientific Officer, Dr. Charles
Dinarello, added, "Findings such as these continue to validate the
broad potential for the use of AAT in several inflammatory conditions
and also highlight the potential for our recombinant Fc fusion
molecule
 to be used in a low-dose, self-administered subcutaneous
format." Presently, treating AAT-deficient patients requires weekly
intravenous infusions and travel to a doctor's office or infusion
center. 
Dr. Bruce Schneider, CEO of Omni Bio, stated, "Omni Bio is very
pleased to have supported Dr. Joosten's work and this first important
disclosure of data on our lead Fc-AAT molecule. We will continue to
foster the research of Fc-AAT to expand our understanding of its
utility in a variety of treatment settings." 
About alpha-1 antitrypsin (AAT) 
AAT is the most abundant circulating serine protease inhibitor in the
body and an acute phase reactant. Systemic deficiency in AAT due to
genetic mutations can result in debilitating liver failure and
chronic lung disease such as emphysema. Lifelong treatment with
plasma-derived AAT, intravenously administered, is indicated for such
patients. Recent evidence suggests that AAT plays an important role
in modulating immunity, inflammation and apoptosis. AAT protects
various cell types from cell death, inhibits caspases-1 and -3
activity and has been shown to be effective in a wide variety of
animal models of human disease, including diabetes, graft versus host
disease (rejection reactions following bone marrow or other
transplantation procedures), gout, myocardial infarction and
inflammatory bowel disease. 
About Omni Bio Pharmaceutical, Inc. 
Omni Bio Pharmaceutical (www.omnibiopharma.com) is a
biopharmaceutical company that is focused on alternative uses for AAT
and on developing new recombinant forms that can be applied to the
treatment of a broad range of indications as noted above. Since its
formation, Omni Bio has supported research using animal models and
human clinical studies that demonstrate that AAT is a promising agent
for ameliorating these conditions. 
Forward-Looking Statements
 Some of the statements made in this press
release are forward-looking statements that reflect management's
current views and expectations with respect to future events. These
forward-looking statements are not a guarantee of future events and
are subject to a number of risks and uncertainties, many of which are
outside our control, which could cause actual events to differ
materially from those expressed or implied by the statements. These
risks and uncertainties are based on a number of factors, including
but not limited to the business risks disclosed in our SEC filings,
especially the section entitled "Risk Factors" in our Annual Report
on Form 10-K for the fiscal year ended March 31, 2012. We undertake
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. 
Contact
Omni Bio Pharmaceutical, Inc.
Bob Ogden
Chief Financial Officer - Investor Relations
(720) 488-4754
Email - investor_relations@omnibiopharma.com